Jasper Therapeutics (JSPR)
NASDAQ:JSPR
Want to see JSPR full AI Analyst Report?
JSPR Stock Chart & Stats
$1.02
-$10.02(-56.58%)
At close: 4:00 PM EST
$1.02
-$10.02(-56.58%)
Day’s Range― - ―
52-Week Range$0.62 - $7.19
Previous CloseN/A
Volume4.28M
Average Volume (3M)399.98K
Market Cap
$23.21M
Enterprise Value$86.38K
Total Cash (Recent Filing)$14.14M
Total Debt (Recent Filing)$757.00K
Price to Earnings (P/E)―
Beta2.45
Next Earnings
Aug 07, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.25
Shares Outstanding27,996,819
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.11
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.88Price Target Upside672.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low absolute debt reduces near-term default and interest expense risk, giving the company more financial flexibility versus highly leveraged peers. This durable balance-sheet feature lowers immediate refinancing pressure and helps preserve cash for clinical development.
Focused Therapeutic PipelineA clear scientific focus on mast-cell biology and a lead asset (briquilimab) creates concentrated development expertise and potential first-mover or niche leadership if clinical trials succeed. A focused pipeline can improve R&D efficiency and strategic clarity over time.
Lean Operating HeadcountA small, lean workforce supports lower fixed operating costs and can extend cash runway per dollar spent on R&D. For a clinical-stage biotech, disciplined headcount helps preserve capital while advancing trials, improving the sustainability of development programs.
Bears Say
Sustained Cash BurnPersistent, large negative operating and free cash flow signals ongoing funding needs to progress clinical programs. Over months, this burn rate increases dependency on external capital, raising execution risk and the likelihood of dilution or disrupted development timelines.
Pre-Revenue Business ModelWithout commercial revenue, the company must rely on financing to fund R&D and operations, making long-term sustainability contingent on trial success or capital markets access. This structural lack of revenues keeps profitability and cash self-sufficiency distant.
Eroded Equity CushionA sharply reduced equity base reflects accumulated losses and/or dilution, leaving little buffer for adverse outcomes. This materially heightens financing sensitivity and reduces strategic flexibility, increasing the probability that future fundraising could be dilutive or restrictive.
Jasper Therapeutics News
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $0.62 and its highest was $7.19 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $23.21M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 67 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on May 14, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.486 by $0.446.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate is -0.26.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 27,996,819 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.486. Following the earnings report the stock price went down -11.366%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
JSPR Stock 12 Month Forecast
Average Price Target
$7.88
▲(672.06% Upside)
Technical Analysis
Ownership Overview
1.34% Insiders
5.12% Mutual Funds
33.47% Other Institutional Investors
55.74% Public Companies and
Individual Investors